TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03893565

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

Cause of deathFunding or business Automatic label, confidence 0.5, unverified. How labels are made.
“The trial was stopped based on the assessment of clinical data.”

The sponsor’s own words in the registry.

Life of this trial

20192020202120222023Registered2019-03-26Started2019-05-06Stopped2021-05-17Results posted2022-04-27

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
GlaxoSmithKline
Sponsor type
Industry
Conditions
Colitis, Ulcerative
Interventions
GSK2831781 - Double Blind Phase; Placebo; GSK2831781 - Open Label phase
Participants
104
Sites
61
Countries
Bulgaria, Czechia, Estonia, France, India, Japan, Netherlands, Poland, Russia, Serbia, Slovakia, South Africa and more

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.